Ibnsina PharmaCAI:ISPH -6.22%87 EBITDA Margin % is 4.09% as of Mar. 2026, which is 6% above its 10-year median of 3.87. GuruFocus rates CAI:ISPH with a GF Score™ of 87/100 and a GF Value™ of E£10.51 (Fairly Valued). The stock has 7 warning signs investors should review. Among 117 Medical Distribution companies, Ibnsina Pharma ranks better than 53.85% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Ibnsina Pharma's EBITDA for the
three
months ended in Mar. 2026 was E£838 Mil. Ibnsina Pharma's Revenue for the
three
months ended in Mar. 2026 was E£20,501 Mil. Therefore, Ibnsina Pharma's EBITDA margin for the quarter that ended in Mar. 2026 was 4.09%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Ibnsina Pharma EBITDA Margin % Related Terms
Ibnsina Pharma EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Ibnsina Pharma's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CAI:ISPH vs MCK, COR, CAH: EBITDA Margin % Comparison
For the Medical Distribution subindustry, Ibnsina Pharma's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ibnsina Pharma EBITDA Margin % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Ibnsina Pharma's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Ibnsina Pharma's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ibnsina Pharma (CAI:ISPH) has a EBITDA Margin % of 4.09% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Ibnsina Pharma and its competitors. This is near median its historical median of 3.87. Over the past decade, Ibnsina Pharma's EBITDA Margin % has ranged from 3.25 to 5.20. According to the industry distribution chart, Ibnsina Pharma ranks #54 out of 117 companies in the Medical Distribution industry, placing it in the top 46.2%.
Is Ibnsina Pharma's EBITDA Margin % too high?
Ibnsina Pharma's current EBITDA Margin % of 4.09% is near median its 10-year median of 3.87. Over the past 10 years, this metric has ranged from a low of 3.25 to a high of 5.20. The Medical Distribution industry median EBITDA Margin % is 4.28. Ibnsina Pharma's value of 4.09% is 4.4% below this industry median. Based on the distribution chart, Ibnsina Pharma ranks #54 out of 117 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, Ibnsina Pharma has a GF Score™ of 87/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Ibnsina Pharma's EBITDA Margin % compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Ibnsina Pharma ranks #54 out of 117 companies for EBITDA Margin %. This puts Ibnsina Pharma in the upper half of its industry. The industry median EBITDA Margin % is 4.28. Ibnsina Pharma's value of 4.09% is 4.4% below this benchmark. Historically, Ibnsina Pharma's own EBITDA Margin % has ranged from 3.25 to 5.20 over the past decade. While the company's 10-year median is 3.87 vs. the industry median of 4.28, Ibnsina Pharma has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Distribution company?
The median EBITDA Margin % among Medical Distribution companies is 4.28, based on 117 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ibnsina Pharma's current EBITDA Margin % of 4.09% is 4.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Ibnsina Pharma and its competitors. For the Medical Distribution industry, the median EBITDA Margin % is 4.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ibnsina Pharma's current EBITDA Margin % is 4.09%, which is near median its own 10-year median of 3.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ibnsina Pharma stock overvalued right now?
Based on GuruFocus' analysis, Ibnsina Pharma (CAI:ISPH) is currently considered Fairly Valued. The stock's GF Value™ is E£10.51, compared to a current price of E£11.30 — trading 7.5% above its estimated fair value. The current EBITDA Margin % is 4.09%, which is near median its 10-year median of 3.87 and 4.4% below the Medical Distribution industry median of 4.28. Ibnsina Pharma's overall GF Score™ is 87/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Ibnsina Pharma (CAI:ISPH), the current EBITDA Margin % is 4.09% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ibnsina Pharma (CAI:ISPH) Overvalued in 2026?
Based on GuruFocus' analysis, Ibnsina Pharma stock appears to be overvalued.
The current stock price of E£11.30 is trading 7.5% above its estimated GF Value™ of E£10.51.
GuruFocus considers Ibnsina Pharma to be Fairly Valued.
Key valuation signals for CAI:ISPH:
EBITDA Margin %: 4.09% (near median its 10-year median of 3.87)
GF Value™: E£10.51 vs. price of E£11.30 (7.5% above fair value)
Industry Position: 4.4% below the Medical Distribution median (#54 of 117)
No single metric tells the full story. See the CAI:ISPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ibnsina Pharma is an Egypt-based pharmaceutical distribution company. It is engaged in purchasing and selling in wholesale and distribution of pharmaceutical, semi- pharmaceutical, and cosmetic products. It distributes a portfolio of pharmaceutical products from local and multinational pharmaceutical companies to retail pharmacies, wholesalers, hospitals, and public health institutions. In addition, the company also offers services including warehousing and logistics, marketing solutions, importation, packaging, market research, and analysis.
87GF Score
Get the complete analysis for CAI:ISPH
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAI:ISPH has been successfully added to your 
